TIS tissue therapies limited

a proper update , page-21

  1. 1,546 Posts.
    lightbulb Created with Sketch. 5
    the players can already satisfy and profit from 50% of the market with their existing product. Anything they pay for new product will only benefit them some portion beyond the first 50%.

    There's this thing called competition!

    If a single player had monopoly control of the market, then sure there'd be no reason for them to push a new product. (Especially as the product is likely to _decrease_ the overall size of the market if it reduces the time patients are under treatment.)

    But in real life there are multiple companies competing for a share of the market. If one of them can offer a product that demonstrates - and the FDA or MAA accepts as having - better efficacy, then they might be able to double or triple their sales.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.